Therapy Areas: Oncology
BioMimetix publishes BMX-001 Phase I/II clinical trial results for head and neck cancer
20 November 2026 -

Biotechnology company BioMimetix JV LLC announced on Thursday the publication of results from a multicentre Phase I/II clinical trial evaluating BMX-001, a redox-active metalloporphyrin compound, in patients undergoing chemoradiation for locally advanced head and neck squamous cell carcinoma (HNSCC).

The single-arm Phase I/II study enrolled 29 patients with stage III–IV head and neck squamous cell carcinoma who received the investigational drug, BMX-001, in combination with chemoradiation therapy. It found that BMX-001 was safe and well tolerated and suggested substantial efficacy in mitigating treatment-related toxicities, including oral mucositis, xerostomia, and radiation dermatitis, in patients who received standard of care chemoradiation.

The results have been published in the International Journal of Radiation Oncology, Biology, Physics.

BMX-001 is a redox-active superoxide dismutase mimic that down-regulates oxidative stress pathways associated with radiation therapy, while stimulating repair pathways. These same impacts of BMX-001 inhibit tumour cell growth because of the unique metabolic pathways active in tumours. Preclinical studies show that BMX-001 protects normal tissues from radiation-induced injury while enhancing tumour responses to treatment.

Login
Username:

Password: